Literature DB >> 28454796

Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial.

Søren Zöga Diederichsen1, Ketil Jørgen Haugan2, Lars Køber3, Søren Højberg4, Axel Brandes5, Christian Kronborg6, Claus Graff7, Anders Gaarsdal Holst8, Jonas Bille Nielsen9, Derk Krieger10, Jesper Hastrup Svendsen11.   

Abstract

Atrial fibrillation (AF) increases the rate of stroke 5-fold, and AF-related strokes have a poorer prognosis compared with non-AF-related strokes. Atrial fibrillation and stroke constitute an intensifying challenge, and health care organizations are calling for awareness on the topic. Previous studies have demonstrated that AF is often asymptomatic and consequently undiagnosed. The implantable loop recorder (ILR) allows for continuous, long-term electrocardiographic monitoring with daily transmission of arrhythmia information, potentially leading to improvement in AF detection and stroke prevention.
METHODS: The LOOP study is an investigator-initiated, randomized controlled trial with 6,000 participants randomized 3:1 to a control group or to receive an ILR with continuous electrocardiographic monitoring. Participants are identified from Danish registries and are eligible for inclusion if 70years or older and previously diagnosed as having at least one of the following conditions: hypertension, diabetes mellitus, heart failure, or previous stroke. Exclusion criteria include history of AF and current oral anticoagulation treatment. When an AF episode lasting ≥6minutes is detected, oral anticoagulation will be initiated according to guidelines. Expected follow-up is 4years. The primary end point is time to stroke or systemic embolism, whereas secondary end points include time to AF diagnosis and death.
CONCLUSION: The LOOP study will evaluate health benefits and cost-effectiveness of ILR as a screening tool for AF to prevent stroke in patients at risk. Secondary objectives include identification of risk factors for the development of AF and characterization of arrhythmias in the population. The trial holds the potential to influence the future of stroke prevention.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28454796     DOI: 10.1016/j.ahj.2017.02.017

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  19 in total

Review 1.  Population-Based Screening for Atrial Fibrillation.

Authors:  Shaan Khurshid; Jeffrey S Healey; William F McIntyre; Steven A Lubitz
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

Review 2.  Digital health solutions in the screening of subclinical atrial fibrillation.

Authors:  Sebastian König; Andreas Bollmann; Gerhard Hindricks
Journal:  Herz       Date:  2021-06-04       Impact factor: 1.443

3.  Impact of transducer frequency setting on speckle tracking measures.

Authors:  Flemming Javier Olsen; Jesper Hastrup Svendsen; Lars Køber; Søren Højberg; Ketil Haugan; Jan Skov Jensen; Tor Biering-Sørensen
Journal:  Int J Cardiovasc Imaging       Date:  2017-11-03       Impact factor: 2.357

4.  Comparison of the three-level and the five-level versions of the EQ-5D.

Authors:  Anne Simone Juhl Christiansen; Marie Louise Sletskov Møller; Christian Kronborg; Ketil Jørgen Haugan; Lars Køber; Søren Højberg; Axel Brandes; Claus Graff; Søren Zöga Diederichsen; Jonas Bille Nielsen; Derk Krieger; Anders Gaarsdal Holst; Jesper Hastrup Svendsen
Journal:  Eur J Health Econ       Date:  2021-03-18

5.  Accuracy, analysis time, and reproducibility of dedicated 4D echocardiographic left atrial volume quantification software.

Authors:  Jesper Hastrup Svendsen; Tor Biering-Sørensen; Flemming Javier Olsen; Litten Bertelsen; Niels Vejlstrup; Caroline Løkke Bjerregaard; Søren Zöga Diederichsen; Peter Godsk Jørgensen; Magnus T Jensen; Anders Dahl; Nino Emmanuel Landler; Claus Graff; Axel Brandes; Derk Krieger; Ketil Haugan; Lars Køber; Søren Højberg
Journal:  Int J Cardiovasc Imaging       Date:  2022-01-03       Impact factor: 2.357

6.  Potential role of conventional and speckle-tracking echocardiography in the screening of structural and functional cardiac abnormalities in elderly individuals: Baseline echocardiographic findings from the LOOP study.

Authors:  Flemming Javier Olsen; Søren Zöga Diederichsen; Peter Godsk Jørgensen; Magnus T Jensen; Anders Dahl; Nino Emmanuel Landler; Claus Graff; Axel Brandes; Derk Krieger; Ketil Haugan; Lars Køber; Søren Højberg; Jesper Hastrup Svendsen; Tor Biering-Sørensen
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

7.  Heart failure and central sleep apnea in the era of implantable recorders.

Authors:  Irina Cabac-Pogorevici; Valeriu Revenco
Journal:  Anatol J Cardiol       Date:  2021-04       Impact factor: 1.596

Review 8.  Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.

Authors:  Emelia J Benjamin; Alan S Go; Patrice Desvigne-Nickens; Christopher D Anderson; Barbara Casadei; Lin Y Chen; Harry J G M Crijns; Ben Freedman; Mellanie True Hills; Jeff S Healey; Hooman Kamel; Dong-Yun Kim; Mark S Link; Renato D Lopes; Steven A Lubitz; David D McManus; Peter A Noseworthy; Marco V Perez; Jonathan P Piccini; Renate B Schnabel; Daniel E Singer; Robert G Tieleman; Mintu P Turakhia; Isabelle C Van Gelder; Lawton S Cooper; Sana M Al-Khatib
Journal:  Circulation       Date:  2021-01-25       Impact factor: 29.690

Review 9.  Subcutaneouscardiac Rhythm Monitors: A Comprehensive Review.

Authors:  Gaurav Aggarwal; Saurabh Aggarwal; Venkata Alla; Bharat Narasimhan; Kyungmoo Ryu; Courtney Jeffery; Dhanunjaya Lakkireddy
Journal:  J Atr Fibrillation       Date:  2021-02-28

Review 10.  Atrial high-rate episodes: a comprehensive review.

Authors:  Gelu Simu; Radu Rosu; Gabriel Cismaru; Mihai Puiu; Gabriel Gusetu; Ioan Minciuna; Sabina Istratoaie; Raluca Tomoaia; Dumitru Zdrenghea; Dana Pop
Journal:  Cardiovasc J Afr       Date:  2021-01-15       Impact factor: 0.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.